Dr. Carl Landgren, MD

Dr. Landgren practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Landgren's NPI, 1972926871, was assigned on January 28, 2014. Dr. Landgren graduated from Karolinska Institute Faculty of Medicine in 1995. Dr. Landgren holds Florida license ME147425.

Dr. Landgren's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Landgren's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Landgren to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Landgren practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Landgren's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Landgren's licenses on file in 3 states: Florida, New York and Maryland.

CMS data shows 820 Medicare services from Dr. Landgren across 4 procedure codes in 2024, for 166 Medicare patients. Medicare paid $58,994 for them. Every service was in an office.

CMS counts 166 Medicare patients who saw Dr. Landgren in 2024. The largest group is 65 to 74, with 93 patients. 71% of them have high cholesterol, and 64% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Landgren's median patient age at 73, with 42% women.

In 2024, Dr. Landgren wrote 36 Medicare Part D claims for 26 patients. 39% of them were for generic drugs. They cover 6 drugs, with $16,927 in total drug cost. In 2019, CMS named 255 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Landgren for performance year 2024, reported as part of a group. Dr. Landgren accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Landgren as offering telehealth.

Dmand AI links 16 papers to Dr. Landgren, published from 2017 to 2025. 2017 was the busiest year, with 5. The most frequent topics are Multiple Myeloma, Neoplasm, Residual and Plasma Cells. Dr. Landgren has published most often in Leuk Lymphoma. Dr. Landgren's most frequent co-authors are Hani Hassoun, MD, Alexander M. Lesokhin, MD and Sham Mailankody, MBBS.

Dmand AI links Dr. Landgren to 2 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Multiple Myeloma, Smoldering Multiple Myeloma and Blood Protein Disorders.

CMS Open Payments shows 458 general payments to Dr. Landgren from 25 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. Amgen Inc. paid the most, $273,518. It also lists 20 research payments totaling $154,266 from 2016 to 2025.

Dr. Landgren graduated from Karolinska Institute Faculty of Medicine in 1995.

Dr. Landgren is in network with 11 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.